Recor Medical Reports 19.6 mmHg Blood Pressure Reduction with Paradise System in Six Months
Recor Medical and its parent company Otsuka Medical Devices announced in a press release that new real-world clinical data presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2025 conference demonstrated a significant blood pressure reduction using the Paradise System for renal denervation.
According to the results from the Global Paradise System (GPS) registry, patients experienced a 19.6 mmHg decrease in systolic office blood pressure after six months of treatment with the ultrasound-based Paradise system. The analysis of pooled data from the global RADIANCE study program also showed a sustained systolic blood pressure reduction of 15.7 mmHg after 24 months.
The Paradise uRDN system is a device-based adjunctive therapy for patients with uncontrolled or resistant hypertension whose blood pressure remains high despite lifestyle modifications and medication.
We hope you enjoyed this article.
Consider subscribing to one of our newsletters like Life AI Weekly or Daily AI Brief.
Also, consider following us on social media:
More from: Life Sciences
Subscribe to Life AI Weekly
Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.
Market report
2025 Generative AI in Professional Services Report
This report by Thomson Reuters explores the integration and impact of generative AI technologies, such as ChatGPT and Microsoft Copilot, within the professional services sector. It highlights the growing adoption of GenAI tools across industries like legal, tax, accounting, and government, and discusses the challenges and opportunities these technologies present. The report also examines professionals' perceptions of GenAI and the need for strategic integration to maximize its value.
Read more